PhaseII study of Nivolumab monotherapy for patients with occupational cholangiocarcinoma
Latest Information Update: 23 May 2019
At a glance
- Drugs Nivolumab (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- Acronyms OPAL
- 22 May 2019 Status changed from not yet recruiting to recruiting.
- 05 Feb 2019 New trial record